title: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
abstract: Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC.
authors.affiliation: Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195 USA.
authors.forename: Brian I
authors.initials: BI
authors.lastname: Rini
authors.affiliation: Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 10 Highfield Circle, Milton, MA 02186 USA.
authors.forename: David F
authors.initials: DF
authors.lastname: McDermott
authors.affiliation: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans St, Baltimore, MD 21287 USA.
authors.forename: Hans
authors.initials: H
authors.lastname: Hammers
authors.affiliation: Kidney Cancer Association, PO Box 4668 #38269, Chicago, IL 60680 USA.
authors.forename: William
authors.initials: W
authors.lastname: Bro
authors.affiliation: Cleveland Clinic Taussig Cancer Institute, 1 Clinic Center, Cleveland, OH 44195 USA.
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Bukowski
authors.affiliation: Patient and Patient Advocate, Cleveland, USA.
authors.forename: Bernard
authors.initials: B
authors.lastname: Faba
authors.affiliation: Patient and Patient Advocate, Cleveland, USA.
authors.forename: Jo
authors.initials: J
authors.lastname: Faba
authors.affiliation: Cedars-Sinai Medical Center, 8700 Beverly Blvd., Saperstein Critical Care Tower, 1S28, Los Angeles, CA 90048 USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Figlin
authors.affiliation: Charles A. Sammons Cancer Center, Baylor University Medical Center, 3410 Worth Street, Suite 400, Dallas, TX 75254, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hutson
authors.affiliation: M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Eric
authors.initials: E
authors.lastname: Jonasch
authors.affiliation: Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
authors.forename: Richard W
authors.initials: RW
authors.lastname: Joseph
authors.affiliation: Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Bradley C
authors.initials: BC
authors.lastname: Leibovich
authors.affiliation: The Ohio State University Medical Center, 320 W. 10th Avenue, Columbus, OH 43210, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Olencki
authors.affiliation: UCLA Institute of Urologic Oncology, 66-124 Center for Health Sciences, Los Angeles, CA 90095, USA.
authors.forename: Allan J
authors.initials: AJ
authors.lastname: Pantuck
authors.affiliation: Kenneth J. Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave Suite 3451, Los Angeles, CA 90033, USA.
authors.forename: David I
authors.initials: DI
authors.lastname: Quinn
authors.affiliation: Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, 10 Highfield Circle, Milton, MA 02186 USA.
authors.forename: Virginia
authors.initials: V
authors.lastname: Seery
authors.affiliation: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
authors.forename: Martin H
authors.initials: MH
authors.lastname: Voss
authors.affiliation: M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Wood
authors.affiliation: Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave, Cleveland, OH 44195 USA.
authors.forename: Laura S
authors.initials: LS
authors.lastname: Wood
authors.affiliation: Georgetown-Lombardi Comprehensive Cancer Center, 3970 Reservoir Road, NW, Research Building, Room E501, Washington, DC 20057, USA.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000494:pharmacology / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D007680:Kidney Neoplasms / Q000628:therapy*
chemical_list: D000074322:Antineoplastic Agents, Immunological
keywords: Guidelines; Immunotherapy; Renal cell carcinoma; Treatment